Pre-Treatment Prediction by Hormone Receptor Subtype of Response to Neoadjuvant Chemotherapy in Node-Positive Breast Cancer Patients; a Radiomics Study

Drukker K.; Edwards A.; Doyle C.; Papaioannou J.; Kulkarni K.; Giger M.

首页> 外文期刊>Medical Physics >Pre-Treatment Prediction by Hormone Receptor Subtype of Response to Neoadjuvant Chemotherapy in Node-Positive Breast Cancer Patients; a Radiomics Study

【24h】

Pre-Treatment Prediction by Hormone Receptor Subtype of Response to Neoadjuvant Chemotherapy in Node-Positive Breast Cancer Patients; a Radiomics Study

机译：核阳性乳腺癌患者新辅助化疗的激素受体亚型预处理预测; 辐射族研究

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Medical Physics》 |2019年第6期|共2页
作者
Drukker K.; Edwards A.; Doyle C.; Papaioannou J.; Kulkarni K.; Giger M.;
展开▼
作者单位

Univ Chicago Chicago IL 60637 USA;

Univ Chicago Chicago IL 60637 USA;

Univ Chicago Chicago IL 60637 USA;

Univ Chicago Chicago IL 60637 USA;

Univ Chicago Chicago IL 60637 USA;

Univ Chicago Chicago IL 60637 USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类基础医学;
关键词

相似文献

外文文献
中文文献
专利

1. Pre-Treatment Prediction by Hormone Receptor Subtype of Response to Neoadjuvant Chemotherapy in Node-Positive Breast Cancer Patients; a Radiomics Study [J] . Drukker K., Edwards A., Doyle C., Medical Physics . 2019,第6期

机译：核阳性乳腺癌患者新辅助化疗的激素受体亚型预处理预测; 辐射族研究
2. Tumor histological subtyping determined by hormone receptors and HER2 status defines different pathological complete response and outcome to dose-dense neoadjuvant chemotherapy in breast cancer patients [J] . Sánchez-Mu?ozA., Plata-FernándezY., FernándezM., Clinical & translational oncology : . 2014,第6期

机译：由激素受体和HER2状态决定的肿瘤组织学亚型定义了乳腺癌患者对剂量密集的新辅助化疗的不同病理完全反应和结果
3. Tumour molecular subtyping according to hormone receptors and HER2 status defines different pathological complete response to neoadjuvant chemotherapy in patients with locally advanced breast cancer [J] . Alfonso Sánchez-Mu?oz, Ana María García-Tapiador, Esther Martínez-Ortega, Clinical and Translational Oncology . 2008,第10期

机译：根据激素受体和HER2状态的肿瘤分子分型定义了局部晚期乳腺癌患者对新辅助化疗的不同病理完全反应
4. Breast MRI radiomics for the pre-treatment prediction of response to neoadjuvant chemotherapy in node-positive breast cancer patients [C] . Karen Drukker, Iman El-Bawab, Alexandra Edwards, SPIE Conference on Computer-Aided Diagnosis . 2019

机译：乳腺MRI辐射射清，用于节点阳性乳腺癌患者对新辅助化疗的反应预处理预测
5. Coregistration of serial breast MR studies for augmenting neoadjuvant chemotherapy response evaluation in breast cancer patients. [D] . Chittineni, Ruparani. 2008

机译：增强乳腺癌患者新系列辅助化疗反应评估的系列乳房MR研究的核心。
6. Breast MRI radiomics for the pretreatment prediction of response to neoadjuvant chemotherapy in node-positive breast cancer patients [O] . Karen Drukker, Alexandra Edwards, Christopher Doyle, 2019

机译：乳腺MRI射频用于预处理对新核乳腺癌患者新辅助化疗的反应预测
7. Assessment of axillary node status by ultrasound after neoadjuvant chemotherapy in patients with clinically node-positive breast cancer according to breast cancer subtype [O] . Yurina Maeshima, Takehiko Sakai, Akiko Ogiya, 2021

机译：乳腺癌亚型临床节律阳性乳腺癌患者患者临床上乳腺癌后超声评估腋窝节点状态

Pre-Treatment Prediction by Hormone Receptor Subtype of Response to Neoadjuvant Chemotherapy in Node-Positive Breast Cancer Patients; a Radiomics Study

著录项

相似文献

相关主题

期刊订阅